Prognostic factors of lymphoma patients after autologous stem cell transplantation
Related Experiment Video
Updated: Apr 14, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Fenghua Qian1, Wenxia Fan1, Xia Wei1
1Department of Hematology, Southwestern Hospital, Third Military Medical University, Chongqing, China (mainland).
Unlabelled:
BacKGROUND: Hematopoietic stem cell transplantation (HSCT) is considered to be a cure for lymphoma. However, factors related to its prognosis remain unclear.
Material And Methods:
Eighty patients diagnosed with lymphoma and treated with autologous HSCT (Auto HSCT) were recruited. The primary endpoints included overall survival (OS) and progression-free survival (PFS).
Results:
After a median follow-up of 37.9 months, the 3-year OS was 75%. Univariate analysis showed age (P=0.020), elevated lactate dehydrogenase (LDH) (P=0.031), international prognostic index (IPI) (P=0.015), Eastern Cooperative Oncology Group (ECOG) (P=0.048), bone marrow involvement (P=0.038), and time to neutrophil recovery (P=0.043) were prognostic factors of lymphoma. Multivariate analysis revealed IPI (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.09-2.34, P=0.016) and time to neutrophil recovery (HR 2.69, 95% CI 1.02-7.07, P=0.045) were independent factors correlated with OS.
Conclusions:
IPI and neutrophil recovery are recommendatory predictors for lymphoma patients after Auto HSCT.
More Related Videos
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...